CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment.
Finding new prognostic factors to identify patients with Hodgkin lymphoma (HL) at risk of treatment resistance or relapse remains challenging in daily practice. We evaluated the relationship between CD68 expression, interim positron emission tomography (iPET) results and outcome in 158 patients with HL diagnosed from February 1995 to July 2011. Immunohistochemistry (anti-CD68) gave two groups: low with ≤25% positive cells (121 patients) and high with >25% (37 patients). Five-year overall survival was higher in the low group (88.4% vs. 63.2%, p=0.0151), as was progression-free survival (74.5% vs. 40.7%, p=0.0003). In 68 patients evaluable, iPET correlated with CD68: 13/52 patients (25%) in the low group had positive iPET as compared to 11/16 patients (68%) in the high group (p=0.0016). This study confirms the prognostic value of CD68 in HL. We found a correlation between CD68 and iPET suggesting potential for a better stratification.
Department of Hematology, CHU Limoges, Dupuytren Hospital , Limoges, F-87042 , France.
Mohamed
M
Touati
Manuela
M
Delage-Corre
Jacques
J
Monteil
Julie
J
Abraham
Stéphane
S
Moreau
Liliane
L
Remenieras
Marie-Pierre
MP
Gourin
Nataliya
N
Dmytruk
Agnès
A
Olivrie
Pascal
P
Turlure
Stéphane
S
Girault
François
F
Labrousse
Pierre-Marie
PM
Preux
Arnaud
A
Jaccard
Dominique
D
Bordessoule
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000096:biosynthesis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis*; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D019788:Fluorodeoxyglucose F18; C067980:CD68 antigen, human; D000097382:CD68 Molecule
CD68; Hodgkin lymphoma; interim FDG-PET; prognosis